Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review ( JACC March 2019-1) is organized by American College of Cardiology (ACC)
Date of Release: February 25, 2019
Term of Approval/Date of CME/MOC/ECME Expiration: February 24, 2020
JACC Journal CME/MOC/ECME is intended for physicians who treat patients with cardiovascular disease.
Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both manifestations of end-organ damage of the metabolic syndrome. Through multiple pathophysiologic mechanisms, CVD and NAFLD are associated with each other. Systemic inflammation, endothelial dysfunction, hepatic insulin resistance, oxidative stress, and altered lipid metabolism are some of the mechanisms by which NAFLD increases the risk of CVD. Patients with NAFLD develop increased atherosclerosis, cardiomyopathy, and arrhythmia, which clinically result in cardiovascular morbidity and mortality. Defining the mechanisms linking these two diseases offers the opportunity to further develop targeted therapies. The aims of this comprehensive review are to examine the association between CVD and NAFLD and to discuss the overlapping management approaches.
Upon completion of this activity, the reader will be able to:
• Integrate the evidence for risk of cardiovascular disease (CVD) events and CVD mortality for patients with nonalcoholic fatty liver disease (NAFLD).
• Explain barriers to screening patients for NAFLD (even for those who are high risk)..
• Recommend statin therapy in patients with NAFLD because the cardiovascular and hepatic benefits outweigh the risk of hepatic toxicity.
• Consolidate the pathophysiologic mechanisms that link NAFLD and CVD.
• Summarize the potential therapies available to NAFLD patients to reduce their risk of CVD.
Additional details will be posted as soon as they are available.